Month: April 2017

When Approval for a Drug “Indication” Gets Murky: Drafting Milestones to Avoid Disputes

According to a recent study by SRS of recent private life sciences deals, disputes over earn-outs arose in about one-third (36%) of all milestones that were expected to be hit by September 2016.[1] While most disputes were not about contract interpretation issues regarding whether an event triggered the milestone or […]